FTI Foodtech flags accounting, governance fixes

On May 11, 2026, FTI Foodtech issued a sweeping corrective disclosure that walks back multiple prior material announcements and exposes serious accounting and governance deficiencies. Key points:

• Cancellation of partnership: The previously announced partnership with Genesis Cosmeceuticals (Jan. 29, 2025) has been cancelled after due diligence raised issues.
• Erroneous option grant: A Feb. 26, 2025 press release about 800,000 stock options granted to consultants was false; the options were never granted.
• Mischaracterized acquisition: The March 4, 2025 announcement of an acquisition of “skin care in a bottle” was actually an internal development, not an acquisition from Illuminate Beverages.
• Management upheaval: Director Douglas Magallon passed away Jan. 19, 2026. CFO Steven Nguyen resigned March 30, 2026. The company failed to promptly announce the July 29, 2025 board resignation of Brian Thomas Hoffman.
• Financing irregularities: In both February 2025 and May 2026, common shares were issued before full payment had been received from investors (1,803,071 shares for ~$216k and 1 million shares for ~$200k, respectively). All funds were eventually collected, but the practice violates proper procedure.
• Accounting reclassifications: Multiple related-party loans and advances are being corrected: $460,968 from related companies to be moved to G&A expenses; a negative $56,167 liability to be reclassified properly; a $34,913 subscription receivable discrepancy was a bookkeeping error.
• Other: The company is working toward reinstatement of trading on the TSX Venture Exchange, implying the stock is currently halted. AGM is scheduled for June 5, 2026.

This news is unequivocally material and negative. The company is essentially invalidating several prior press releases that could have misled investors. The corrections point to weak internal controls, poor disclosure practices, and potential regulatory consequences. The trading halt further underscores the severity. For a microcap stock already trading near all-time lows ($0.18), the erosion of credibility and the vacuum in leadership (no permanent CFO, an unfilled independent director slot) create substantial uncertainty. While the company frames the release as “fixes,” the sheer volume of errors and the need for a full accounting cleanup indicate deep-rooted problems. Any remaining shareholder confidence is likely to be shattered, and the shares — if and when trading resumes — will face heavy selling pressure.

FTI Foodtech appears to have pivoted into consumer health/cosmeceutical products, as evidenced by the references to Genesis Cosmeceuticals and “skin care in a bottle.” The limited historical record does not provide a clear flagship asset. The confusion over whether skin care in a bottle was an acquisition or internal development raises serious questions about the company’s actual product pipeline.